07:53 AM EDT, 03/26/2026 (MT Newswires) -- NovoCure ( NVCR ) said Thursday that its phase 2 trial of tumor treating fields, or TTFields, therapy combined with atezolizumab and chemotherapy met its primary endpoint in metastatic pancreatic ductal adenocarcinoma.

The company said the trial showed a statistically significant improvement in disease control rate, with treated patients achieving a 74.4% rate compared with 48% in patients receiving gemcitabine and nab-paclitaxel alone in the historical control group.

Among secondary endpoints, the combination therapy produced an objective response rate of 34.6% and a median overall survival of 9.7 months, NovoCure ( NVCR ) said.

The company said TTFields therapy was well-tolerated, with device related safety consistent with prior clinical studies.

Shares of the company were up 1.6% in premarket activity Thursday.